Cyclerion Therapeutics, Inc. (CYCN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

-2M 0 2M 4M 6M Q1 '20: 5.5M Q2 '20: 4.6M Q3 '20: 3.6M Q4 '20: 2.3M Q1 '21: 1.3M Q2 '21: 3.6M Q3 '21: 3.5M Q4 '21: 3.9M Q1 '22: 4.6M Q2 '22: 1.9M Q3 '22: 1.6M Q4 '22: 297K Q1 '23: -414K Q2 '23: -720K Q3 '23: -720K Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 194K Q4 '24: 2M Q1 '25: 2.1M Q2 '25: 2.2M Q3 '25: 2.9M Q4 '25: 2.1M Q1 '26: 2M Q2 '26: 1.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '18: -115.3M Q1 '19: -127.3M Q2 '19: -130.6M Q3 '19: -129.4M Q4 '19: -125M Q1 '20: -108.2M Q2 '20: -94.9M Q3 '20: -88.6M Q4 '20: -81.3M Q1 '21: -74.1M Q2 '21: -70.6M Q3 '21: -60.1M Q4 '21: -55.2M Q1 '22: -54.8M Q2 '22: -52M Q3 '22: -45.3M Q4 '22: -18.5M Q1 '23: -8.8M Q2 '23: 2.7M Q3 '23: 1.2M Q4 '23: -12.9M Q1 '24: -11.3M Q2 '24: -10.8M Q3 '24: -5.9M Q4 '24: -3.6M Q1 '25: -3.5M Q2 '25: -3.8M Q3 '25: -3.6M Q4 '25: -5M Q1 '26: -6.7M Q2 '26: -6.8M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '18: -115.3M Q1 '19: -127.3M Q2 '19: -129.8M Q3 '19: -127.9M Q4 '19: -123M Q1 '20: -105.9M Q2 '20: -93.1M Q3 '20: -84.6M Q4 '20: -77.8M Q1 '21: -64.5M Q2 '21: -61.2M Q3 '21: -53.7M Q4 '21: -45.2M Q1 '22: -51.2M Q2 '22: -48.4M Q3 '22: -47.6M Q4 '22: -44.1M Q1 '23: -38.1M Q2 '23: -28.8M Q3 '23: -10.8M Q4 '23: -5.3M Q1 '24: 149K Q2 '24: 3M Q3 '24: -5.3M Q4 '24: -3.1M Q1 '25: -2.9M Q2 '25: -1.9M Q3 '25: -2.2M Q4 '25: -3.5M Q1 '26: -5.3M Q2 '26: -6.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q4 '18: -97.5M Q1 '19: -105.3M Q2 '19: -104.7M Q3 '19: -103.2M Q4 '19: -102.2M Q1 '20: -97.1M Q2 '20: -89.4M Q3 '20: -80.6M Q4 '20: -72.5M Q1 '21: -57.8M Q2 '21: -49.1M Q3 '21: -41.9M Q4 '21: -36.5M Q1 '22: -34.9M Q2 '22: -40.2M Q3 '22: -42.2M Q4 '22: -40.6M Q1 '23: -34M Q2 '23: -29.7M Q3 '23: -26.7M Q4 '23: -21.2M Q1 '24: -16.9M Q2 '24: -11.5M Q3 '24: -6.2M Q4 '24: -4.3M Q1 '25: -3.4M Q2 '25: -2.8M Q3 '25: -1.4M Q4 '25: -3.3M Q1 '26: -3.5M Q2 '26: -4.5M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q4 '18: -100.9M Q1 '19: -110.4M Q2 '19: -113.7M Q3 '19: -111.7M Q4 '19: -109.1M Q1 '20: -103.6M Q2 '20: -91.7M Q3 '20: -82.3M Q4 '20: -74M Q4 '18 Q2 '19 Q4 '19 Q2 '20 Q4 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '21: 35.7M Q3 '21: 43.3M Q1 '22: 43.4K Q2 '22: 2.2M Q3 '22: 2.2M Q1 '23: 2.2M Q2 '23: 2.3M Q3 '23: 2.8M Q1 '24: 2.5M Q2 '24: 2.5M Q3 '24: 2.5M Q1 '25: 2.6M Q2 '25: 3.1M Q3 '25: 3.2M Q1 '26: 4.2M Q2 '26: 4.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '18: -4.21 Q1 '19: -4.66 Q2 '19: -4.75 Q3 '19: -4.68 Q4 '19: -4.50 Q1 '20: -3.86 Q2 '20: -3.38 Q3 '20: -2.97 Q4 '20: -2.57 Q1 '21: -2.23 Q2 '21: -1.98 Q3 '21: -1.65 Q4 '21: -1.34 Q1 '23: -17.51 Q2 '23: -13.18 Q3 '23: -5.63 Q4 '23: -2.25 Q1 '24: 0.33 Q2 '24: 1.63 Q3 '24: -1.38 Q4 '24: -1.21 Q1 '25: -1.15 Q2 '25: -0.73 Q3 '25: -0.74 Q4 '25: -1.16 Q1 '26: -1.36 Q2 '26: -1.66 Q2 '19 Q2 '20 Q2 '21 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.